Ubs Oconnor LLC Bio Xcel Therapeutics, Inc. Transaction History
Ubs Oconnor LLC
- $1.46 Billion
- Q3 2024
A detailed history of Ubs Oconnor LLC transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 16,000 shares of BTAI stock, worth $8,160. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,000Holding current value
$8,160% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding BTAI
# of Institutions
55Shares Held
3.14MCall Options Held
22.2KPut Options Held
40.2K-
Vanguard Group Inc Valley Forge, PA1.2MShares$612,7020.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$224,7490.0% of portfolio
-
Geode Capital Management, LLC Boston, MA298KShares$152,0010.0% of portfolio
-
Wells Fargo & Company San Francisco, CA185KShares$94,3790.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny130KShares$66,2330.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $14.3M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...